Navigation Links
Jubilant Enters Research Collaboration With AstraZeneca
Date:5/5/2009

NOIDA, India, May 5 /PRNewswire/ --

- Research Collaboration to Provide AstraZeneca With New Preclinical Drug Candidates

Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.

AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialization of any of the compounds.

Commenting on this Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and

Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are very pleased to partner with AstraZeneca, this collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca's preclinical portfolio and anticipates significant rewards from successful downstream milestones. This partnership furthers Jubilant's strategy to be India's largest provider of innovative and integrated pharmaceutical solutions, enabling the global pharmaceutical industry's quest to discover affordable innovative medicines."

Jan Lundberg, Executive Vice-President, Global Discovery, at AstraZeneca says, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable Discovery pipeline with a lean and agile organization. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com

About Jubilant Biosys

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd.,provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

For more information please visit: http://www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.For more information please visit: http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For further information contact:

    For Media:
    Seema Ahuja
    Jubilant Organosys Limited
    Ph:     +91-120-4361062
    Mobile: +91-9810631779
    email:seema_ahuja@jubl.com

    For Business Queries: Europe and APAC:
    Saurabh Kapure
    Senior Manager Business Development
    Jubilant Biosys and Jubilant Chemsys Ltd.
    Direct: +91-80-6662-8852
    e-mail: saurabh_rk@jubilantbiosys.com

    For Investors:
    Deepak Malik
    Jubilant Organosys Limited
    Tel: +91-120-4361114
    Fax: +91-120-2516629
    E-mail: deepak_malik@jubl.com

    For Business Queries: USA
    Corey Jacklin
    Director, Business Development
    Jubilant Biosys
    Tel: +1-215-369-0965
    E-mail: Corey_Jacklin@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
2. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
3. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
4. Another LNA-based RNA Inhibitor Enters Clinical Trials
5. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
6. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
7. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
8. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
9. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):